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Background: Studies have indicated that the commonly used osteoporosis prescreening tools are not appropriate
for use in every nation. This study was designed to develop and validate a prescreening model for bone mineral
densitometry among Iranian postmenopausal women.
Methods: From 13613 individuals who were referred for bone mineral densitometry in Shariati hospital in Tehran,
8644 postmenopausal women were considered for the study after excluding men and premenopausal women.
Questionnaires regarding the risk factors for osteoporosis were filled for each individual. Bone mineral density at the
lumbar vertebrae (L2-L4), femoral neck and total femur was measured by dual X-ray absorptiometry. Using holdout
validation, the study sample was divided into two parts; training set (5705) and test set (2939). Logistic regression
analysis was performed on the training set. A scoring model was developed and tested in the test set.
Results: Based on the training set, a seven-variable model named OPMIP (Osteoporosis Prescreening Model for Iranian
Postmenopausal women) was developed with C statistics (area under curve) of 0.72. Using a cut-off of -2.5 for the
model, the sensitivity, specificity, positive predictive value and negative predictive value were 72%, 59.5%, 64% and
69% respectively. The model performance was tested in the test set. OPMIP correctly classified 67.10% of cases with a
sensitivity and specificity of 73.2% and 61%.
Conclusions: In order to appropriately refer patients for a bone mineral densitometry, OPMIP can be used as a
prescreening tool in Iranian Postmenopausal women.
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Osteoporosis, the so-called silent disease, is the most com-
mon metabolic disease. Bones become fragile insidiously
and as a result fractures with high morbidity and mortality
rates, occur [1]. Because of the high morbidity and mortal-
ity affecting both the patient and the society, osteoporosis
is often regarded as a global public health challenge. It is
considered a health priority in Iran and a major contribu-
tor of the global burden of non-communicable diseases.
With growing numbers of the elderly in industrialized
countries, the prevalence of osteoporosis and hip fractures
increase. Already an established problem in the United* Correspondence: asadim@tums.ac.ir
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unless otherwise stated.States and European countries, it is appearing as a major
public health problem in Asian countries as well. The
growing number of the elderly and improved quality of life
in these regions is a contributing main factor [2]. The inci-
dence of hip fractures is estimated to rise from 1.66 mil-
lion in 1990 to 2.26 million by 2050, of which 50% occur
in Asia. Industrialized countries have a higher rate of
osteoporotic hip fracture compared with that of develop-
ing countries. The rates are highest in Northern Europe
and the US and lowest in Africa and Latin America. Al-
though Iran is a developing country, the relative high rate
of osteoporotic hip fractures is comparable to that of the
US and other industrialized countries [3,4]. The age-
standardized incidence of annual hip fractures in Iranian
women is 7th in the world, higher than the US and many
other European countries [5]. Iran contributes 0.85% andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Middle East, respectively [6]. Geographical properties,
genetics, ethnicities, latitude, population demographics
and other environmental causes, influence osteoporosis
prevalence and its complications.
Currently the best and most recommended method
for diagnosing osteoporosis is bone mineral densitom-
etry (BMD) using dual-energy X-ray absorptiometry
(DXA). However DXA scan is not recommended as a
screening tool for the whole population. Also according
to the latest IOF (International Osteoporosis Founda-
tion) audits, DXA is not available everywhere. Moreover,
densitometry is overused in some areas and underused
in some others, influenced by availability and socioeco-
nomic factors [7].
With DXA being rather expensive and unavailable in
some areas, developing prescreening tests, often referred
to as the triage tests, is of benefit [8]. The first attempt
to develop such a tool was performed by Slemenda in
1990 [9]. The model was later considered a poor model.
Many other studies evaluated such models [10]. The
most commonly used models in this regard are the
SCORE (Simple Calculated Osteoporosis Risk Estima-
tion) and the ORAI (Osteoporosis Risk Assessment
Instrument) models, developed in 1998 by Lydick et al.
and Cadarette et al. in 2000, respectively. They reported
that SCORE is 89% sensitive and 50% specific, while
ORAI is 95% sensitive and 41% specific [11,12]. Other
models include Osteoporosis Self-Assessment Tool (OST),
Study of Osteoporotic Fractures Simple Useful Risk Factors
(SOFSURF), Osteoporosis Index of Risk (OSIRIS) and age,
body size, no estrogen (ABONE) [13].
Based on previous studies, available prescreening
models have not shown promising results in Iranian
women [14]. Brief analysis in this data showed that these
models are not sensitive enough. With regards to these
analyses and unpublished academic theses, formerly pro-
posed international models are not compatible with
Iranian women; either these models should be calibrated
or other prescreening tools should be developed [15].
The aim of the present study is to develop a simple and
accurate prescreening tool for identifying patients at risk of
osteoporosis who benefit from a DXA scan. So that osteo-
porosis screening is neither overused nor underutilized.
Materials and methods
Subjects
The study was conducted on 13613 who had undergone
bone mineral densitometry in the BMD center of Shariati
referral teaching hospital in the Iranian capital, Tehran,
between April 2001 and April 2012. Patients referred for
BMD, were referred by their family physicians or their
specialists in the fields of endocrinology, rheumatology or
nephrology.Considering the low prevalence of Osteoporosis in men
and premenopausal women, these groups were excluded
from the study, leaving 8644 postmenopausal women, eli-
gible for the study. The study was approved by the ethics
committee of Endocrinology and Metabolism Research In-
stitute affiliated to Tehran University of Medical Sciences.
Measurements
A standard questionnaire on different osteoporosis risk fac-
tors was filled for every patient who was referred to this
center. This questionnaire included details about demo-
graphic and anthropometric data (age, height, weight),
gynecological and hormonal history (age at menarche, age
at menopause, number of children, reproductive history),
medical history (co-morbid conditions such as diabetes,
rheumatoid arthritis, liver diseases, renal diseases, thyroid
diseases, pathologic fractures, etc.) personal and family
history of osteoporotic fractures, current lifestyle habits
(physical activity and sunlight exposure, smoking, alco-
hol consumption and daily intake of dairy products) and
concomitant medication use (glucocorticoids, diuretics,
antipsychotics, antidepressive, antithrombotic and anti-
convulsant drugs). Each participant completed a written
informed consent and the ethics committee of Endocrine
and Metabolism Research center in Tehran University of
Medical Sciences approved this study.
Any physical activity performed for more than 30 mi-
nutes, at least three times a week, other than daily routines
was defined as regular exercise. This included weight bear-
ing exercises (such as jogging, walking and aerobic exer-
cises) and resistance (such as weight lifting and body
building) exercises. Appropriate walking was defined as
walking at medium speed, at least 20 minutes, daily or at
least more than three times a week. The use of medication
or supplements was considered positive when used for
more than three months. Dairy product intake was catego-
rized into three groups: no servings, up to three servings,
more than three servings. Use of vitamin D, Calcium sup-
plements and hormone replacement therapy for more
than three months were also considered.
Bone densitometer measurements were done using
DXA machine (Lunar, 7164, GE, Madison, WI) in Shariati
hospital BMD center. According to the World Health
Organization (WHO); osteoporosis is defined as a BMD of
at least 2.5 standard deviations below the mean for young
adults of the same race and sex (T score). Osteopenia is
defined as a T score of 1.0 to 2.5 SDs below the mean [16].
According to most guidelines, the lumbar spine, femoral
neck and total hip are regions of interest. (9) Most frac-
tures occur with a T score that is 2 standard deviations
(SDs) below the mean for young adults, thus the fracture
threshold was defined and used [12,17-19].
A value of 2 or more SDs below the mean T score in
either one of the lumbar spine, (L2 to L4 vertebrae) total
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threshold; the outcome of interest in this study.
Statistical analysis
After excluding men and premenopausal women, 8644
post-menopausal women were eligible for this study.
“True validation” or “holdout validation” was used to
evaluate the model. Using random sampling, the study
sample was divided into two parts; 66%, equal to 5705 of
the cases, called learning sample or training set, which
were allocated to the development of the model as in
true validation, and 33%; one third of the dataset, named
test sample or test set (comprising 2939 individuals) al-
located to validation of the model. This method is called
the holdout method, the simplest cross validation [20].
A clear view is shown in Figure 1.
At first, descriptive analysis was performed on the
whole dataset. After dividing the dataset into training
and test set as mentioned above, analysis for developing
the model in the training set begun. Chi-square was used
to estimate the effect of each variable with the outcome
(BMD of 2 or more SDs below the mean T score in
either one of the three regions of interest) as the
dependent variable. Logistic regression analysis with
stepwise approaches was applied in the development of
the model. We used β coefficient of each variable. Esti-
mates were then rounded to the nearest integer and
multiplied by 10, to develop a suitable scoring model.
Using plotting receiver operating characteristic (ROC)
curves, the area under the ROC curve, sensitivity, speci-
ficity, positive and negative predictive values and those
correctly classified were determined at each threshold
score. The area under curve, also called C statistic was
estimated. A suitable cut-off point was selected with
regards to sensitivity and specificity. The accuracy of the
scores was then evaluated using the test set, which was
left aside so far and not engaged in the model develop-
ment process. In order to select and validate the final
criteria for our scoring model, the model was applied to
the test set, using ROC analyses. P-values less than 0.05Study population
Figure 1 The study population and how it got divided for analysis.were considered statistically significant. The analysis was
performed using STATA, version 11.2.
Results
In order to categorize patients based on their osteopor-
osis results, T score was used in three regions; the lum-
bar vertebrae (L2-L4), the neck of femur and total hip.
As already mentioned, osteoporosis is defined as a value
of 2.5 standard deviations below the mean in any one of
these three regions. Osteopenia or low bone mineral
density is defined as the T score of 1 standard deviation
or more below the mean. This classification is based on
World Health Organization Diagnostic Criteria for
Women without Fragility Fractures [16]. In this study,
osteopenia is divided into two groups based on the value
of 2 or more standard deviations below the mean which is
defined as the fracture (referral threshold) [12,17-19].
Thus, two groups of osteopenic patients are defined: those
who should be referred for DXA and those who shouldn’t.
Others are classified as normal bone mineral density.
Table 1 shows the frequency of the two osteopenic groups
in both training and test set.
In this study, the dependent or outcome variable was
BMD value of at least 2 or more standard deviations below
the young adult T score mean. During the analysis, at-
tempts were made for selection of the best form (catego-
rized, dichotomous or linear) of each predictor variable.
Those variables which were selected for the multivariate
model, based on bivariate analysis, are shown in Table 2.
The definition of variables is mentioned in the previous
section. In this table, body mass index (BMI), age and years
since menopause are categorized, however due to better
performance of the model when linear; these variables
were not categorized in the model. Ages of the patients
ranged from 23 to 94 (mean ± standard deviation: 58.99 ±
8.69), menopause age ranged from 18 to 69 (47.07 ± 6.42)
and BMIs ranged from 14.02 to 55.24 (27.91 ± 0.06).
Since in this study a large number of patients, with large
number of variables were investigated, many predictor
variables became statistically significant. So variables: 13613 individuals
Table 1 Frequencies of patients in each osteoporosis category based on T-scores in training and test sets








Normal T-scorea 1548(28.37%) 1939(35.63%) 2479(45.54%) 1009e (17.68%) 2643 (46.32%)f
Osteopenic but has not reached the
fracture(refer) thresholdb
1515(27.76%) 1867(34.31%) 1683(30.92%) 1634(28.64%)
Osteopenic patients who should have
been referredc
744(13.63%) 718(13.19%) 587(10.78%) 870(15.24%) 2825 (49.51%)g
Osteoporotic patients who should
have been referredd
1650(30.24%) 918(16.87%) 694(12.75%) 1955(34.26%)
Test set L2-L4 Femoral Neck Total Femur Either one of the regions Important summations
Normal T-scorea 821(29.29%) 998(35.68%) 1307(46.75%) 531(18.06%) 1364 (46.41%)f
Osteopenic but has not reached the
fracture(refer)threshold
740(26.40%) 982(35.11%) 892(31.90%) 833(28.34%)
Osteopenic patients who should have
been referredc
417(14.88%) 395(14.12%) 291(10.41%) 483(16.43%) 1445 (49.16%)g
Osteoporotic patients who should have
been referredd
825(29.43%) 422(15.09%) 306(10.94%) 962(32.73%)
Notes:
aNormal = BMD value within 1 SD of the young adult mean.
bThose with a low BMD however have not reached the referral threshold. Meaning those with a BMD value of between −1 SD and −2 SD (Fracture or referral
threshold) below the young adult mean.
cThose with a low BMD who should be referred. Meaning those with a BMD value of between −2 SD and −2.5 SD below the young adult mean.
dThose with BMD value of at least −2.5 below the young adult mean.
eA patient is considered as normal BMD when neither one of the regions has a BMD value of at least less than −1 SD below the young adult mean.
fThis summation indicates patients below the referral threshold. (Negative outcome of interest).
gThis summation indicates patients who should have been referred. (Positive outcome of interest).
BMD: Bone mineral Density, SD: Standard Deviation.
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based on the results of bivariate analyses and clinical
grounds. Complex variables were also excluded because
this model is designed for a broad use and should be read-
ily applied in different areas of the country. Seven pre-
dictor variables were considered for inclusion in this
model. These predictors include age, body mass index,
years since menopause, corticosteroid use (more than
three months), diabetes, appropriate walking and regular
exercise. Since these two variables are easily biased, we ex-
amined the model with and without these two variables,
using logistic regression and backward approach. Table 3
presents the discriminatory performance of the models in-
cluding 5, 6 and 7 variables. Finally, a seven-variable
model was selected. Using categorized variables lowered
the performance of the model.
Table 4 presents the final model. Rounding the β coef-
ficients for simplicity and multiplying them by 10; Our
Osteoporosis Prescreening Model for Iranian Postmeno-
pausal women (OPMIP) was developed.
ROC (receiver operating characteristic) curve analysis
was performed on the final scoring model. The ROC curve
for the model in the training set is shown in Figure 2. The
full model has a C statistic (area under curve) of 0.72 (95%
CI: 0.71-0.74) and a Hosmer Lemeshow statistic of 10.40
(P-value: 0.23). Based on the ROC curve analysis, a cut-off
point of −2.5 was selected as appropriate for this model.
The score of −2.5 correctly classifies 66% of patients witha sensitivity of 72.60% and specificity of 59.45%. The
OPMIP score of −2.5 or more, identifies 72% of women
with a BMD score of 2 or more SDs below the mean who
should be referred for a DXA scan.
To this point, analyses were performed on the training
set. Next, the model was internally validated using the
test set. The performance of the model did not differ sig-
nificantly in the training and test datasets. In the test
sample, the model had a sensitivity of 73.2% and specifi-
city of 61% and correctly classified 67.10% of cases. The
performance of the model in the training and test data-
sets, considering the cut-off point, is shown in details in
Table 5.
Discussion
In this study, a prescreening seven-variable model was
developed and tested. This model was 72% sensitive and
accurately classified about 67% of patients.
Since the introduction of osteoporosis prescreening
methods, several studies have been organized for triag-
ing postmenopausal women for bone mineral densitom-
etry, because screening all women is not cost-effective.
All of these clinical stratification methods are intended
to introduce a balance between the costs and the fact
that anyone who might benefit from diagnosis should
not be missed. Best validated tests are Osteoporosis Self-
Assessment Tool, based on an Asian study population
[21], the Osteoporosis Risk Assessment Instrument from
Table 2 Predictors of T score of ≤ 2 SDs in the training set
Training set Number of patients who
should be referred (%)
Number of patients with
osteoporosis (%)
Diabetes mellitus Yes 307(10.86) 214(10.94)
No 2518(89.13) 1741(89.05)
Appropriate walking Yes 1196(42.33) 778(39.79)
No 1629(57.66) 1177(60.20)
Regular exercise Yes 126(4.46) 76(3.88)
No 2699(95.53) 1879(96.11)
Using corticosteroids Yes 360(12.74) 270(13.81)
No 2465(87.25) 1685(86.18)
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Calculated Osteoporosis Risk Estimation from United
States population [22]. However because of the varying
performance of the original cut points proposed in dif-
ferent populations and lack of validation in different
study groups, they have yet to be used internationally.Table 3 Performance of different multivariate models based o
Model Area under curve Sensitivity % Specificity % Positive pred
1 0.66 56.00 69.25 64.31
2 0.68 57.76 70.69 66.08
3 0.71 62.39 69.52 66.69
4 0.71 62.02 70.19 67.19
5 0.72 63.01 69.76 67.22
6 0.72 63.04 70.11 67.50
7 0.72 63.07 70.04 67.54
8 0.72 63.23 70.08 67.57
1: age, 2: age and years since menopause, 3: age, years since menopause, BMI, 4:age, y
diabetes and corticosteroid use, 6:age, years since menopause, BMI, diabetes, corticost
corticosteroid use and regular exercising. 8: age, years passed since menopause, BMI, dThese models might not be applicable in every nation
because of the multifactorial nature of osteoporosis. Fac-
tors such as genetics, ethnicity, geographic and cultural
backgrounds, nutrition and different life styles are con-
tributed to different images of osteoporosis in different
areas. Thus the validity and accuracy of these modelsn the number of variables









ears since menopause, BMI and diabetes, 5:age, years since menopause, BMI,
eroid use and appropriate walking, 7: age, years since menopause, BMI, diabetes,
iabetes, corticosteroid use, regular exercising and appropriate walking.
Table 4 The final results of the multivariate analysis and the developed scoring system (OPMIP)
Variable β coefficient (95% CI) Odds ratio (95% CI) Standard error P value Score
Age at entry 0.04 (0.02_0.05) 1.04 (1.03_1.05) 0.0052 0.000 0.4
Years passed since menopause 0.04 (0.03_0.05) 1.04 (1.03_1.05) 0.0051 0.000 0.4
Body mass index −0.11 (−0.13_-0.10) 0.88 (0.87_0.90) 0.0068 0.000 −1
Diabetes mellitus −0.42 (−0.60_-0.24) 0.65 (0.54_0.77) 0.0903 0.000 −4
Corticosteroid 0.60 (0.41_0.80) 1.83 (1.51_2.22) 0.0979 0.000 6
Regular exercise −0.31 (−0.57_-0.05) 0.73 (0.56_0.94) 0.1325 0.018 −3
Appropriate walking −0.20 (−0.32_-0.08) 0.81 (0.72_0.91) 0.0608 0.001 −2
Constant 0.45 (−0.19_1.1)
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vices Task Force evaluated and reviewed these models,
considering their methodological limitations such as lack
of generalizability and lack of validation and concluded
that these models should be further reviewed and ap-
proved [10]. A systematic review, evaluating 48 of such
tools, of which 20 were externally validated, reported
that only six tools were acceptable with regards to their
method: OST, ORAI, Garvan, and SCORE, FRAX
(WHO Fracture Risk Assessment Tool and Qfracture.
This study concluded that none of these prescreening
tools improved the selection of patients who would
benefit from treatment [23].
Numerous studies have evaluated the use of these
models in different ethnicities. One study revealed that
the ORAI sensitivity ranged from 0.60 to 0.68 when used

















Area under ROC curve = 0.7272
Figure 2 The ROC curve for the OPMIP in the training set.populations. The same study, reported a sensitivity of
0.80, 0.30 and 0.71 in the same population for SCORE
[24]. In the Danish Osteoporosis Prevention Study, the
sensitivity of ORAI, SCORE and OSTA ranged from 18
to 92% and the specificity ranged from 66 to 85%. They
also reported a variation in different study sites; for in-
stance, OST was 92% sensitive in the femoral region
compared with 51% in the lumbar spine region [25]. An-
other population based study, using the area under curve
(AUC) for discriminating between the prescreening
tools, concluded an AUC of 0.70 for ORAI, SCORE, OS-
IRIS and OST, different from previous studies [26].
These studies support the idea that one model might
not be applicable to all ethnicities and populations.
When SCORE was first developed and validated in
1998- based on femoral neck BMD of 2 or more SDs
below the mean-scores higher than 6 had a sensitivity of.50 0.75 1.00
pecificity











Training set 0.7273, (0.71-0.74) 72.6, (70.9-74.3) 59.5, (57.6-61.2) 64, (62.1-65.5) 68.8, (67–70.6) 66.68
Test set 0.7280, (0.70-0.74) 73.2, (70.8-75.5) 61, (58.4-63.6) 65, (62.6-67.4) 69.7, (67.1-72.2) 67.10
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developed in 2000, had a sensitivity of 95%, specificity of
41% when equal to or greater than 9 [12]. A sensitivity
of 98% and a specificity of 29% were also reported for
OST [21]. Other models with area under curve (AUC) s
of ≤0.6 are also available. They are not classified in the
“good” quality rated models [10,27].
Further studies were conducted to evaluate the per-
formance of these models. Results revealed that these
models have lower discriminating power than previously
assumed. One study, designed to asses diagnostic accur-
acy of OST,ORAI and SCORE in women aged 67 years
and more, concluded an AUC of 0.76, 0.70 and 0.73,
sensitivities of ≥85% and specificities of ≤48%, for OST,
ORAI and SCORE, respectively. In that study, the out-
come variable was defined as the lumbar or femoral
neck T score of 2.5 or more SDs below the mean T score
[28]. A Korean study, yielded AUCs of 0.79,0.79,0.76 and
0.78 for OST,ORAI, SCORE and OSRIRIS, respectively.
Sensitivities ranged from 0.65 to 0.76 [29]. One study re-
vealed that OST performs poorly for predicting osteo-
porosis in the lumbar spine and moderately in the
femoral neck, which yields to different sensitivities and
specificities based on the outcome of interest [30]. An-
other study, showed a sensitivity of 68% for ORAI and
54% for SCORE in overall accuracy evaluating Hispanic,
NonHispanic and African-American women. The AUC
was 74% for ORAI and 67% for SCORE [24].
One study in Iran showed acceptable performance of
OST and ORAI, with sensitivity and specificity of around
70% and 60% respectively [31]. Another study in Iran indi-
cated that a large number of bone mineral densitometries
(BMDs) performed based on the preformed prescreening
models, were not necessary. It indicated that OST and
ORAI lead to 60% and 50% unnecessary DXA scans, re-
spectively. It also reported that only 50% of the BMDs were
appropriate based on SCORE and ORAI. International
Osteoporosis Foundation guidelines conducted only 33.3%
appropriately. About 40% of BMDs were appropriately per-
formed using OST and OSIRIS models and only 10%,
based on ABONE. So, these prescreening tools are not
suitable for Iranian population and relying on them leads
to unnecessary tests around the country [14]. Applying
these models to the data used in this paper was not an ob-
jective of this study; however a rough estimate in the early
analyses phase, not published yet, revealed that applying
OST, SOFSURF and OSIRIS, has a sensitivity of only 30 to50%. ABONE, SCORE and ORAI were more compatible
with this data, being around 60 to 70% sensitive, with low
specificity and low Positive and Negative Predictive Values,
which are important characteristics of a risk assessment
tool. The AUC for these models, ranged from 0.57 to 0.68,
confirming that they are not suitable decision making tools
for a DXA scan. This analysis showed that these models
lack the sensitivity for a “good” prescreening tool. Not be-
ing representative of every population in the world, na-
tional attempts should be made to develop a suitable
model for each nation. Studies have also concluded that
using these models have caused unnecessary DXA scans,
not only in Iran but also in many other countries [7,14,32].
Many reasons explain this varied performance. First
the dependent (outcome) variables used for stratifying
patients are different in these prescreening models. That
is; while the OST uses femoral neck T score equal to or
less than −2.5, ORAI uses femoral neck or lumbar spine
T score equal to or less than −2 and SCORE uses fem-
oral neck T score equal to or less than −2 as dependent
variable. This inconsistency leads to variable perform-
ance. Recently, osteoporosis is defined based on bone
mineral density in either one of these three regions of
interest: Femoral neck, lumbar spine or the total femur
area [33]. Moreover, these models should be used for
prophylactic maneuvers and treatment threshold is far
from prescreening goals. It means that T-score of ≤ −2.5
is too late for prophylactic maneuvers. This is while the
Fracture Threshold (T score of 2 or higher) is an accept-
able alternative in this regard and can be used for
screening women for DXA. Another limit for these
models is the use of hormone replacement therapy
(HRT). In fact, when ORAI and SCORE were proposed,
HRT use was prevalent because of highly positive atti-
tude towards them, which proved to be overly optimistic
later [34,35]. HRT is not prevalent these days; a finding
also confirmed in this study. Other limits for these
models, is the overlooked effects of environment and life
style on bone health. Life styles, habits and diets vary
significantly among the different areas of the world.
Some studies have reported different anatomical sites of
osteoporosis across different racial groups, for example
the lumbar spine is more likely to be involved in osteo-
porosis than the hip in African-American women [36].
In this study, for the first time, we developed a model
based on logistic regression analysis and holdout method
using a group of postmenopausal women. The holdout
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menopausal women), into two samples, one to develop
the model (5705 women) and the other one for testing
the model (2939). (Internal Validity) The cut off of −2.5
was calculated for the model named OPMIP. In other
words, individuals with OPMIP score of more than −2.5
should be referred for DXA. The area under curve was
0.72 which is considered “good” for a prescreening or
screening model. The Hosmer Lemeshow statistic of
10.40 indicated that the model is well calibrated. Our
model has a sensitivity of 72% and specificity of 60%,
correctly classifying 66% of cases. The positive and nega-
tive values of our model were 64% and 68% respectively.
Although this study has many positive points such as
the large sample size, limits are yet to be confronted. The
studied population might not be representative for the
whole Iranian population, since BMD center was located
in a referral hospital in Tehran, the capital of the country.
In fact, participants who are referred for BMD measure-
ment might have more risk factors (like the use of gluco-
corticoids) than postmenopausal women in the general
population. Also appropriate walking and regular exercise,
which are proposed as independent variables in this study,
were assessed based on self-reports. The fact that the out-
come is based on the fracture threshold in three regions is
a double-sided sword. The positive point is the accuracy
and the correct definition of outcome. However, this
model is not totally comparable to others because of dif-
ferent dependent variables. Further studies should be done
to evaluate and compare this model with other available
models. Also, the holdout method might not be efficient
for estimating internal validity and might be weaker than
other cross validation methods [37]. Another limit is that
we have not examined our model in other study popula-
tion. We can’t conclude that this method is good enough
for all rural and urban areas and family medicine centers.
The model might be too complex for a nationwide use.
Attempts should be made to develop a simple algorithm
for this method to make it feasible in every medical center.
The development of other statistical softwares and better
statistical methods might also provide a better decision
tool for this purpose. One point is important however, that
financial limits highlight the need of simple prescreening
models for DXA testing which is the ultimate purpose in
this study and many similar studies.
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